|
|
|
|
| Join our experienced panelists as they break down how to transform your CDMO partnerships from sources of stress into strategic assets. Register for free thanks to support from Simtra. More info here! |
|
|
|
| Why CROs Need A New Operating System | Article | By Ander Tallett, Dash Bio | See why building digital, automated infrastructure is essential, and better aligns CROs with today's speed, compliance, and innovation needs. |
|
|
| Mirror, Mirror Makes RNA-targeted Discovery Smarter | Article | By Zhen Chen, X-Chem | Examine a mirror‑image screening approach that eliminates DNA:RNA hybridization, revealing true binders and unlocking clearer, more productive DEL results for challenging RNA targets. |
|
|
| Qualities Of A CDMO Redefining Innovation | Infographic | Grand River Aseptic Manufacturing | High-volume biologics and home-based care requires specialized expertise. Collaborative partnerships bridge the gap between complex drug-delivery requirements and successful commercial market entry. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | “I assist C-suite executives to transfer quality from a painful cost center to a competitive asset." It's the type of bold statement that draws one's attention. Chief Editor Louis Garguilo asked David Grote on what his assertion means materially – and how that’s applied to working with CDMOs. Here's their discussion that focuses on a transformation that moves executives from regarding quality as ‘overhead’ to recognizing quality as “an operational element for business advantage.” | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Essential Insights Into Linker Chemistry For ADCs | Article | Abzena | The linker is key to an ADC's success, influencing stability and targeted drug release. Explore the evolution of linker chemistry, from cleavable mechanisms to site-specific conjugation. |
|
|
| From Syringes To Wearables: Formulation's Impact | Article | Andreas Stelzl, Ph.D. and Eva Keilhauer, Ph.D., Coriolis Pharma | High‑concentration biologic formulations for prefilled syringes and on‑body devices enable easier self‑administration, reduce treatment burden, boost adherence, and address formulation challenges. |
|
|
|
|
|
|
| Solid‑State HDX For ADC Stability | White Paper | Simtra BioPharma Solutions | Discover how this solid-state HDX-MS is being used to revolutionize the prediction of stability for IgG-based antibody drug conjugates and enhance ADC development processes. |
|
|
|
| Application Of Plant And Process Models | White Paper | Boehringer Ingelheim Biopharmaceuticals GmbH | Assimilate how innovative process and facility models that optimize efficiency, sustainability, and cost-effectiveness in biopharmaceutical manufacturing. |
|
|
|
Inside Our Advanced R&D Capabilities In The UK | Asymchem | Advanced experimentation, unified workflows, and continuous manufacturing are accelerating small‑molecule development, improving insight and creating more efficient paths from discovery to scale. |
|
|
Large Molecule Capabilities In Network | Novartis Contract Manufacturing | Gain insight into our global manufacturing network, including information about the capabilities of each mammalian and microbial site within the network. |
|
|
Improving CHO Cell Line Productivity | KBI Biopharma | Advanced CHO cell line development methods can improve stability, yield, and overall biologic quality. These approaches also help resolve bottlenecks with support. |
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
